The company will leverage the funds to build a commercially scalable GMP manufacturing facility and continue developing its extensive portfolio of potentially curative gene therapies along with the UT Southwestern Gene Therapy Program
FREMONT, CA: Texas-based patient-centric gene therapy company with a mission to eradicate monogenic CNS disease, Taysha Gene Therapies, secured USD 95 million in an oversubscribed Series B funding round with a premier syndicate of life science investors. Fidelity Management & Research Company LLC was the lead investor for this round, with BlackRock, GV (formerly Google Ventures),ArrowMark Partners, Casdin Capital, Franklin Templeton, Octagon Capital, Perceptive Advisors LLC, InvusSands Capital, and Venrock Healthcare Capital Partners also participating the round. Founding investors PBM Capital and Nolan Capital also participated in the funding round. Proceeds from the investment round will be used for advancing the initial cohort of lead programs into the clinic and accelerate progress on anticipated IND submissions. The company will leverage the funds to build a commercially scalable GMP manufacturing facility and continue developing its extensive portfolio of potentially curative gene therapies along with the UT Southwestern Gene Therapy Program.
"This significant investment from premier, long-term investors will allow us to advance our mission of eradicating monogenic CNS disease for the thousands of patients who suffer from these devastating disorders," said RA Session II, President, CEO, and Founder of Taysha. "We remain on track and expect to file four Investigational New Drug (IND) applications by the end of 2021, with TSHA-101 initiating clinical studies later this year for the treatment of GM2 Gangliosidosis." The company is working on a deep and sustainable pipeline of 17 gene therapy product candidates, with exclusive options to acquire four additional programs across three distinct franchises. This includes neurodegenerative diseases, neurodevelopmental disorders, and genetic forms of epilepsy.
The company's TSHA-101 is expected to start clinical studies this year for the treatment of GM2 Gangliosidosis, followed by TSHA-102 for treating Rett syndrome, TSHA-103, for treating SLC6A1 haploinsufficiency disorder and TSHA-104 for treating SURF1 deficiency. The company is expected to file INDs for each of these four product candidates by the end of 2021.
"We have brought together experts in gene therapy with leading healthcare and institutional investors to create a company that is uniquely positioned to advance the development of potentially curative gene therapies for CNS disease in rare and large patient populations," said Sean Nolan, Chairman of the Board of Taysha. "We believe this financing provides significant validation of our corporate strategy and will enable us to continue to rapidly translate programs from preclinical development into the clinic."